David A. Siegel Crinetics Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 31,800 shares of CRNX stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,800
Previous 38,800
18.04%
Holding current value
$1.45 Million
Previous $1.38 Million
7.83%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CRNX
# of Institutions
221Shares Held
75.8MCall Options Held
631KPut Options Held
749K-
Black Rock Inc. New York, NY5.44MShares$248 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.23MShares$238 Million2.68% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.95MShares$225 Million0.59% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.16MShares$189 Million5.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$174 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.45B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...